Skip to main content

Table 2 General study parameters

From: Factors affecting the value of diffusion-weighted imaging for identifying breast cancer patients with pathological complete response on neoadjuvant systemic therapy: a systematic review

First author Year Study design Age (y) Patients (DWI) Lesions Initial stage NST (cycles) pCR rate (%)a Molecular subtype*
Woodhams [64] 2010 Prospective/single center   69 70   CA-T(4+4) 12.9  
Tozaki [40] 2010 Prospective/single center 46 (27–61) 7 7 II FEC 75(1) or FEC 75(4) or FEC 100(4) or FEC 75(2) or weekly Pac(4) 14.3  
Fangberget [65] 2011 Prospective/single center 50.7 (37–72) Pre: 31
4 cy: 27
32   FEC(4+2), FEC(4)-T(+trastuzumab if HER2+) 36.6b TN: 4
ER+: 21
HER2 enriched: 5
ER/Pr−/Her2+: 1
Shin [26] 2012 Retrospective/single center   41    CA(4), C-T(4+4), TA, FEC 36.6  
Fujimoto [66] 2014 Retrospective/single center 50.9 ± 10.0 (29–70) 56   II and III Different regimesc 14.3d HER2+: 17
Hormone+: 40
Hahn [67] 2014 Retrospective/single center 43.3 (24–59) 1.5 T: 28
3.0 T: 50
78 II and III Different combinations according to receptor status 24.4 ER+: 40/78
HER2+: 23/78
Bufi [17] 2015 Retrospective/single center 47 ± 10.1 225   II, III and IV Combination of TAC (not specified) 17.3e Luminal: 143
TN: 37
HER2+/enriched:: 17
Hybrid: 28
Li [44] 2015 Prospective/single center Median 46 (28–67) Start: 42
1 cy: 36
  II and III Different combinations 33.3 TN: 12
Hormone+: 19
HER enriched: 11
Liu [16] 2015 Retrospective/single center 53.2 (28–68) 176   II and III 4 cycles Doxo + cyclophos (once/3 wks)-4 cycles docetaxel (once/2 wks) Luminal A: 13.3
Luminal B: 11.9
TN: 34.3
HER2-enriched: 20.7
Luminal A: 67
Luminal B: 45
TN: 35
HER2-enriched: 29
Che [19] 2016 Not specified 50.9 ± 11.0 Pre: 36
Pre and 2 cy: 28
  II and III TA(4–8) or TCAR 19.4 Luminal A: 4
Luminal B: 26
Basal like: 4
HER2-enriched: 2
Bedair [20] 2017 Prospective/single center Median 53 (32–75) Pre: 36
2 cy: 22
36   HER2−: Docetaxel(3)-FEC(3)
2pt: Taxol-FEC
HER2+: FEC(3)-Taxol Docetaxel + trastuzumab
38.8 ER+: 24/36
HER2: 13/36
Minarikova [59] 2017 Prospective/single center 52 ± 10 (29–74) 42 42   CA-T(4+4), T-CA(4+4), TA (6 or 8) 16.7 HER2+: 5
TN: 12
ER+ & PR+: 14
Santamaria [27] 2017 Retrospective/single center 54 (27–84) 111    TA(6) (+trastuzumab in HER2+) 18.9 TN: 20
HER2+: 51
ER+/HER2−: 40
Gallivanone [21] 2017 Retrospective/single center 48 ± 12 (28–72) Baseline: 38
Surgery: 31
     Luminal A: 24%
Luminal B: 21%
HER2-enriched: 13%
TN/basal: 42%f
Yuan [22] 2018 Prospective/single center 47.3 ± 11.0 (pCR)
43.3 ± 10.0 (non-pCR)g
Pre till incl. 6 cy: 142
8 cy: 118
  II and III CA-T(4+4) or T-CA(4+4)
TA(4,6 8)
Extra to NAC: some cases trastuzumab in HER 2+
28.2 Luminal A: 25
Luminal B: 44
Basal like: 40
HER2-enriched: 33
Partridge [23] 2018 Prospective/multi center 48 ± 10 Pre: 242
Pre & 3 cy: 227
Pre & 12 cy: 210
Pre & post: 186
   Pac ± exp agent(12)-A(4) 33 TN: 77
HER2-enriched: 24
Hormone positive: 141
Kim [53] 2018 Retrospective/not specified 45 (25–67) 46    A/cyclophos
A/T
A/cyclophos + T
A/T + trastuzumab
30.4h (pCR: 10.9)  
Ramirez-Galván [25] 2018 Prospective/single center 48.5 ± 7.8 14 16   Cyclophos + epirubicin(4)-Pac(12)
Or Clyclosphos + doxorubicin(4)-Pac(12)
HER2+: trastuzumab
Drug toxicity: replace by Carboplatin
25 Hormone+: 7
TN: 5
HER2-enriched: 4
Zhang [24] 2018 Retrospective/single center 52 ± 12.6 (26–73) 61   II and III Pac + cisplatin
HER2: also trastuzumab
39.3 Luminal & HER2+: 30
Luminal & HER2−: 31
Pereira [18] 2019 Prospective/single center 45 (27–65) 62 62   All AC-T based:
In HER2: + trastuzumab
Or AC-T + carboplatin
Or AC-T +  (pertuzumab + Trastuzumab and docetaxel)
38.7 TN: 22
HER2-enriched: 10
Luminal B-Ki-67: 23
Luminal B-HER2: 7
  1. n.r. not reported, TN triple negative, HER2 human epidermal growth factor receptor 2, DCIS ductal carcinoma in situ, CA-T anthracycline and cyclophosphamide, followed by taxane, T-CA vice versa, TA taxane (-based) and anthracycline, FEC 5-fluoro-uracil, epirubicin and cyclophosphamide, T taxane based, CAR carboplatin, Pac paclitaxel, A anthracycline, cy cycles, base baseline, Doxo doxorubicin, Cyclophos cyclophosphamide, wks weeks
  2. *Not all studies specified all molecular subtypes
  3. aPatients/lesions
  4. b11/30 lesions, for two patients no surgery, therefore not included in the 30 lesions
  5. cAdriamycin and cyclophosphamide (every 3 weeks), 12 weekly doses of taxanebased OR 4 cycles FEC (once every 3 weeks) followed by 4 cycles taxane based (paclitaxel)
  6. dJapanese Breast Cancer Society criteria, grade 3
  7. eTumor regression grade (TRG) 1
  8. fThe percentage can be too high, see [21]
  9. gOverall mean age not reported
  10. hGood responders based on Miller and Payne grade 4